TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07010159: Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387

Sponsor: Kiniksa Pharmaceuticals International, plc · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 325 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,118,808

Rescue Site Savings

+$2,065,704

Unlock Full NCT07010159 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07010159 Rescue Dossier →